CHECKMATE 816 was the first phase 3 study to evaluate neoadjuvant nivolumab plus chemotherapy in patients with resectable stage IB–IIIA non-small cell lung cancer (per the AJCC seventh edition staging system) with no epidermal growth factor receptor (EGFR)/ALK mutations [81]. This evidence concerns the gene ALK and non-small cell lung carcinoma.